News | May 15, 2007

Boston Scientific’s OLYMPIA Trial Registers 23,000

May 16, 2007 — Boston Scientific Corp. has announced that it has completed enrollment in the European and Intercontinental phases (II and III) of its TAXUS OLYMPIA registry, bringing the total number of current patients to more than 23,000.

The registry is designed to evaluate the safety and performance of the Company's second-generation drug-eluting coronary stent (DES), TAXUS Liberte, in a real-world setting. OLYMPIA is the world's largest DES registry and plans to enroll at least 27,000 patients treated for complex coronary lesions at more than 400 centers worldwide.

"The size of the OLYMPIA registry is truly unprecedented in the DES field and will yield invaluable real-world information to the benefit of interventional cardiologists and those patients who suffer from cardiovascular disease," said Martyn Thomas, M.D., F.R.C.P., director of Invasive Cardiology, Kings College Hospital, London, and one of the coordinating investigators of the registry. "We expect the results from this registry to remain consistent with the safety and efficacy results we've seen in previous clinical trials featuring the TAXUS stent system in complex patients with complex lesions."

The multi-center, prospective, observational OLYMPIA registry will evaluate a variety of safety and performance measures, including the rate of repeat procedures (target lesion revascularization, or TLR) and major adverse cardiac events. Additionally, sub-analyses on complex patient groups such as diabetics, patients with multi-vessel disease, in-stent restenosis (re-blockages) or a prior history of heart attack will be performed.

For more information visit www.bostonscientific.com.

Related Content

Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Biosensors, BioFreedom drug-coated stent, LEADERS FREE II IDE trial, first patient, U.S. pivotal study
News | Stents Drug Eluting| March 03, 2017
Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS FREE II, its new...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents| January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Overlay Init